Company Overview of ProNAi Therapeutics, Inc.
ProNAi Therapeutics, Inc., a DNA interference (DNAi) focused biopharmaceutical company, develops and commercializes therapies that target DNA to treat patients with cancer and other complex genetic diseases. It develops nucleic acid-based DNAi technology, a gene-silencing drug that attacks cancer and prolongs survival by turning off cancer genes at their source with a small piece of DNA delivered in a fatty particle. The company’s PNT2258 is designed to treat cancers that overexpress BCL2. Its products pipeline also includes drug candidates to treat non-Hodgkin’s lymphoma, melanoma, prostate, breast, and colon cancers. ProNAi Therapeutics, Inc. was incorporated in 2003 and is based in Plymou...
46701 Commerce Center Drive
Michigan Life Science and Innovation Center
Plymouth, MI 48170
Founded in 2003
Key Executives for ProNAi Therapeutics, Inc.
Co-Founder and Chief Executive Officer
Chief Scientific Officer and Vice President of Product Development
Director of Technology and Business Development
Compensation as of Fiscal Year 2014.
ProNAi Therapeutics, Inc. Key Developments
ProNAi Therapeutics, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM
Jun 10 14
ProNAi Therapeutics, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Mina Patel Sooch, Chief Executive Officer, President and Director.
ProNAi Therapeutics Mulls IPO
Jan 12 14
ProNAi Therapeutics, Inc. has engaged a major New York investment bank to start raising $30 million and planning for an initial public offering by the end of 2014. Chief Executive Officer Mina Sooch says ProNAi is poised to take advantage of the results of its phase two Food and Drug Administration. Mina Sooch said she cannot name the New York investment bank, which has a focus on health care companies, because it requires confidentiality until it has successfully raised money.
ProNAi Therapeutics, Inc. Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, Novel BCL2-Inhibitor, at ASH Annual Meeting
Dec 9 13
ProNAi Therapeutics, Inc. presented safety and efficacy data from its ongoing Phase II study on December 09, 2013 at the 55(th) Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana. Phase II findings on the company's first-in-class BCL2 targeted IV drug were presented in an oral session on Novel Therapies for Lymphoma, titled The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma. PNT2258's mechanism of action targets the BCL2 gene directly, rather than the BCL2 protein, to inhibit cancer cell proliferation, drive cell death (apoptosis) and minimize off-target effects. PNT2258 Phase II Data Presented at ASH on December 8, 2013 (Abstract #88): PNT2258, a first-in-class BCL2 targeted drug, exhibits single agent anti-tumor activity in patients with recurrent or refractory NHL. 82% of patients had tumor shrinkage when receiving single-agent therapy with PNT2258. To date, overall response rate in patients with follicular lymphoma (FL) is 40% and in patients with diffuse large B-cell lymphoma (DLBCL) is 50%. Several patients have elected to receive additional maintenance therapy after their planned 6 treatment cycles. PNT2258 is safe at a dose of 120 mg/m2 IV administered for 2-3 hours on days 1-5 of a 21-day schedule. No tumor lysis syndrome or major organ toxicities were observed. No occurrences of elevated liver enzymes, hyperkalemia, hyperphosphatemia, hypocalcemia, renal failure/dysfunction, or infections were noted. Additionally, no Grade 4 toxicities. PNT2258 drug exposures levels (AUC) exceeded by at least four-fold that required for anti-tumor activity in xenograft studies of human tumors, consistent with the Phase I study. Preliminary pharmacodynamic markers demonstrated on-target BCL2 activity, including lymphocyte and platelet effects. With the promising results in DLBCL and FL patients, additional PNT2258 single-agent and combination studies are planned.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 17, 2014
January 10, 2014
December 20, 2013